Open AccessCLINICAL AND ECONOMIC EVALUATION OF ATEZOLIZUMAB + VEMURAFENIB + COBIMETINIB COMBINATION AND NIVOLUMAB + IPILIMUMAB COMBINATION: ADMINISTRATION IN METASTATIC MELANOMA TREATMENT WITH BRAF-CONFIRMED MUTATION IN ADULT PATIENTS
Author(s) -
I. Krysanov,
Ekaterina Makarova,
V. Ermakova
Publication year - 2022
Publication title -
farmaciâ i farmakologiâ
Language(s) - English
Resource type - Journals
eISSN - 2413-2241
pISSN - 2307-9266
DOI - 10.19163/2307-9266-2022-10-3-278-288
Subject(s) - nivolumab , ipilimumab , medicine , metastatic melanoma , atezolizumab , oncology , vemurafenib , melanoma , overall survival , cancer research , cancer , immunotherapy